<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588442</url>
  </required_header>
  <id_info>
    <org_study_id>2018ZX10732202</org_study_id>
    <nct_id>NCT03588442</nct_id>
  </id_info>
  <brief_title>Prospective Surveillance for Very Early Hepatocellular Carcinoma</brief_title>
  <acronym>PRECAR</acronym>
  <official_title>Prospective Surveillance for Very Early Hepatocellular Carcinoma (PRECAR): an Observational Cohort Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eastern Hepatobiliary Surgery Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma is one the leading cause of increasing cancer-specific mortality
      worldwide. Early diagnosis of hepatocellular carcinoma provides opportunity for curative
      therapeutic approaches and relatively favorable prognosis. Herein, we intended to establish a
      biosignature for early diagnosis of hepatocellular carcinoma and stratification of risk
      population for intensive follow-up by implementing biannual follow-up investigation and
      collecting peripheral blood samples for screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited for 1 year and be follow-up for 3 years. Patients will make active
      hospital visit for collection of blood samples, which will be analyzed to develop a
      biosignature at the end of the study to detect very early hepatocellular carcinoma and
      stratify risk population for intensive follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatocellular carcinoma</measure>
    <time_frame>July 2018 to July 2022</time_frame>
    <description>Development of hepatocellular carcinoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>July 2018 to July 2022</time_frame>
    <description>Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver-related disease progression</measure>
    <time_frame>July 2018 to July 2022</time_frame>
    <description>HBV and cirrhosis progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-hepatocellular carcinoma malignant neoplasm</measure>
    <time_frame>July 2018 to July 2022</time_frame>
    <description>Development of other primary liver cancer, such as Intrahepatic cholangiocarcinoma.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Cirrhosis cohort</arm_group_label>
    <description>Patients with liver cirrhosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV infection cohort</arm_group_label>
    <description>Patients with seropositivity of HBsAg.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cirrhosis cohort: patients with liver cirrhosis. HBV infection cohort: patients with
        chronic HBV infection.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -

        [1] Cirrhosis cohort

          1. Age within 30 to 75 years.

          2. Diagnosis of liver cirrhosis within recent 6 months.

          1. Liver biopsy: Metavir score of 4 or Ishak score of 5 to 6.

          2. No liver biopsy: Presence of ascites, hepatic encephalopathy, or variceal hemorrhage.

          3. Satisfying equal to or more than 2 of below conditions.

               -  Imaging studies indicating characteristics of liver cirrhosis: irregular liver
                  surface, liver parenchyma particles or nodules, intraperitoneal collateral
                  circulation, or varicose veins with or without splenomegaly (more than 4 cm or 5
                  ribs).

               -  Platelet count &lt; 200 x 10^9/L.

               -  Alanine aminotransferase &lt; 5 folds of normal level and liver hardness &gt; 12 kPa.

               -  Gastroesophageal varices from endoscopy or imaging studies.

                  [2] HBV infection cohort

                    1. Age within 40 to 70 years

                    2. Chronic HBV infection (seropositive for HBsAg over 6 months).

                       Exclusion Criteria:

                         1. Cirrhosis cohort

                  (1) Child-Pugh score of C.

                  (2) Hereditary metabolic liver diseases.

                  (3) Presence of HIV-Ab.

                  (4) Previous diagnosis of active pulmonary tuberculosis.

                  (5) Diagnosis of malignant tumors before or during hospitalization, including but
                  not limited to hepatocellular carcinoma.

                  (6) Patients who had received allogeneic blood transfusion or cell therapy within
                  1 year.

                  (7) Pregnant women.

                  [2] HBV infection cohort

                  (1) Autoimmune liver diseases.

                  (2) Hereditary metabolic liver diseases.

                  (3) Other chronic liver diseases, such as flukes.

                  (4) Presence of HCV, HDV, HEV, or HIV infection.

                  (5) Previous diagnosis of active pulmonary tuberculosis.

                  (6) Diagnosis of malignant tumors before or during hospitalization, including but
                  not limited to hepatocellular carcinoma.

                  (7) Patients who had received allogeneic blood transfusion or cell therapy within
                  1 year.

                  (8) Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongyang Wang, MD and PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jinlin Hou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongyang Wang, PhD</last_name>
    <phone>86 21 81875361</phone>
    <email>hywangk@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Chen, PhD</last_name>
    <phone>86 13918939969</phone>
    <email>chenlei@smmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital Affiliated to AMU (Southwest Hospital)</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaomei Xiang, BM</last_name>
      <phone>15023263301</phone>
      <email>xiangxiaomei413@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mengchao Hepatobiliary Surgery Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolong Liu, MD</last_name>
      <phone>13313975783</phone>
      <email>xiaoloong.liu@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Fan, MD</last_name>
      <phone>13143522264</phone>
      <email>rongfansmu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Central Hospital of Wuhan</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Du, PhD</last_name>
      <phone>15926366269</phone>
      <email>treacy29@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chifeng Municipal Hospital</name>
      <address>
        <city>Chifeng</city>
        <state>Inner Mongolia</state>
        <zip>024000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanlong Yu, MM</last_name>
      <phone>15247666626</phone>
      <email>yuyanlong1895@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou No.1 People's Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqian Liu, MM</last_name>
      <phone>13952173003</phone>
      <email>zbliuxiaoqian@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Infectious Disease Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhanzhong Liu, PhD</last_name>
      <phone>18352222280</phone>
      <email>Zhanzhong.liu@foxmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Bethune of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanhang Gao, MD</last_name>
      <phone>15804303019</phone>
      <email>15804303019@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutao Du, MD</last_name>
      <phone>13573132466</phone>
      <email>dulutao1984@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiao Liu, MD</last_name>
      <phone>18930328039</phone>
      <email>liujiao8812@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Oriental Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Wang, MD</last_name>
      <phone>13816444416</phone>
      <email>13816444416@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Xinjiang Medical University</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hali Da, MM</last_name>
      <phone>18509914924</phone>
      <email>28043284@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HwaMei Hospital, University of Chinese Academy of Sciences</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xudong Zhao, MD</last_name>
      <phone>15990575156</phone>
      <email>zhaoxudong120@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eastern Hepatobiliary Surgery Hospital</investigator_affiliation>
    <investigator_full_name>Lei Chen, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03588442/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

